TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36448816

Group type: EXPERIMENTAL
Intervention: Enterocheck WB
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: CTK IgG
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Enterocheck
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Nine commercially available Salmonella Typhi RDTs
Number of subjects: 531
Study: 36449027

Group type: EXPERIMENTAL
Intervention: Reoperation (surgical management)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 91
Study: 36449262

Group type: EXPERIMENTAL
Intervention: Lenadogene nolparvovec gene therapy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Bilateral injection of lenadogene nolparvovec
Number of subjects: 174

Group type: COMPARATOR
Intervention: Natural history
Number of subjects: 174
Study: 36449285

Group type: EXPERIMENTAL
Intervention: Blue light phototherapy
Number of subjects: 0
Study: 36449335

Group type: EXPERIMENTAL
Intervention: ePRO app (electronic Patient-Reported Outcome)
Number of subjects: 0
Study: 36449341

Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (standardized delivery format)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (self-tailored delivery format)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 205
Study: 36449446

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36449695

Group type: EXPERIMENTAL
Intervention: neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Higher SUVmax at cycle 2 (C2)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Baseline TILs and DTILs
Number of subjects: 202
Study: 36450120

Group type: EXPERIMENTAL
Intervention: Chronic Pelvic Pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asymptomatic Controls
Number of subjects: 0
Study: 36450289

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adherence and depression (CBT-AD) delivered by a nurse, conducted once weekly for 12 sessions.
Number of subjects: 5
Study: 36450379

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg intravenously every 3 weeks)
Number of subjects: 0
Study: 36450384

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: History of immune-related adverse events (irAEs)
Number of subjects: 240
Study: 36450385

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 1 mg/kg and Ipilimumab (IPI) 3 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 3 mg/kg and Ipilimumab (IPI) 1 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) induction therapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Biomarker analyses
Number of subjects: 56
Study: 36450386

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) followed by nivolumab (240 mg every 2 weeks for up to 24 doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 42
Study: 36450427

Group type: EXPERIMENTAL
Intervention: Surgical procedures (intervention group)
Number of subjects: 1353

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1353
Study: 36450746

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccine
Number of subjects: 764
Study: 36450763

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab (TH)
Number of subjects: 366
Study: 36450938

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) at a dose of 5 mg/kg 24 hours prior to surgery
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: NIRF imaging
Number of subjects: 51
Study: 36450944

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) measuring neck fluid volume (NFV) and leg fluid volume (LFV) at preoperative, PACU, N 0, and POD 1 time points
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Feasibility measures of recruitment and protocol adherence
Number of subjects: 35
Study: 36451004

Group type: EXPERIMENTAL
Intervention: Glittre ADL Test
Number of subjects: 25
Study: 36451029

Group type: COMPARATOR
Intervention: Intravenous spesolimab (0.01-0.3 mg/kg and ≥ 0.3 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous spesolimab (150-600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous spesolimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous spesolimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study: 36451062

Group type: EXPERIMENTAL
Intervention: Tween-20 detergent lysis (DLT) method with 2-h incubation at 37 °C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tween-20 detergent lysis (DLT) method with 4-h incubation at room temperature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated freeze-thaw (RFT) method
Number of subjects: 0
Study: 36451114

Group type: EXPERIMENTAL
Intervention: Intensive inpatient treatment program (APT + VITA)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: APT
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: VITA
Number of subjects: 280

Group type: COMPARATOR
Intervention: Wait list (TAU)
Number of subjects: 280
Study: 36451162

Group type: EXPERIMENTAL
Intervention: Compression ultrasonography (CUS) of proximal lower limb veins within 48 hours from admission and at discharge
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: D-Dimer measurement and IMPROVE-DD score assessment
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: CUS at admission
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 2100
Study: 36451175

Group type: EXPERIMENTAL
Intervention: Decentralized PWUD-HCV care model using pangenotypic direct acting antivirals (DAAs) for HCV treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interviews with addiction care professionals and board members.
Number of subjects: 0
Study: 36451198

Group type: COMPARATOR
Intervention: 4D flow CMR parameters in PAH patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RV direct flow
Number of subjects: 45
Study: 36451226

Group type: EXPERIMENTAL
Intervention: Tobacco cessation services received, assessed using the S-KAS scale after 12 months of follow-up.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Self-reported practices in smoking cessation by clinicians, assessed using the S-KAP scale.
Number of subjects: 250
Study: 36451242

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fimasartan 60 mg/amlodipine 10 mg (FMS/ALD)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fimasartan 60 mg + rosuvastatin 20 mg (FMS + RSV)
Number of subjects: 138
Study: 36451252

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injections (0.5 mg/0.05 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravitreal conbercept (IVC) injections (0.5 mg/0.05 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both IVR and IVC
Number of subjects: 80
Study: 36451311

Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 3142
Study: 36451312

Group type: EXPERIMENTAL
Intervention: Extracellular vesicle long RNA (evlRNA) sequencing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SVM model based on a 23-gene signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SVM model based on a 17-gene signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EvlRNAs in serum
Number of subjects: 0
Study: 36451848

Group type: EXPERIMENTAL
Intervention: Dupilumab, a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13.
Number of subjects: 0
Study: 36452171

Group type: EXPERIMENTAL
Intervention: BL10 gel
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EMLA gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 18
Study: 36452315

Group type: EXPERIMENTAL
Intervention: Quantitative information in a decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Qualitative information in a decision aid
Number of subjects: 0
Study: 36452492

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate and TRIS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicarbonate
Number of subjects: 0
Study: 36452901

Group type: EXPERIMENTAL
Intervention: AGT103-T autologous T cell therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide conditioning
Number of subjects: 0
Study: 36452951

Group type: EXPERIMENTAL
Intervention: Telehealth consultations proposed and accepted in almost 40% of cases.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-drainage as a replacement for physiotherapy sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotropic medications usage.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social class impact on behavior and healthcare access.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual follow-up clinic visits.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Required hospitalizations for exacerbation.
Number of subjects: 0
Study: 36453122

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection (pain group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline injection (control group)
Number of subjects: 20
Study: 36453450

Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol
Number of subjects: 0
Study: 36453455

Group type: EXPERIMENTAL
Intervention: Most elliptical annulus tertile
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Circular annulus
Number of subjects: 1732
Study: 36453629

Group type: EXPERIMENTAL
Intervention: 10,000 steps per day physical activity intervention for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group of age-matched patients with Marfan syndrome
Number of subjects: 24
Study: 36453638

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation (UCBT) using either 5/6 or 6/6 UCB as the cell source, with fully ablative busulfan, cyclophosphamide, and fludarabine without serotherapy.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation (UCBT)
Number of subjects: 55
Study: 36453656

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) ≥140 mmHg at age 40-43 years
Number of subjects: 2424

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) <120 mmHg at age 40-43 years
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Change in SBP during the 25-year follow-up
Number of subjects: 2424
Study: 36453667

Group type: EXPERIMENTAL
Intervention: Pilates intervention, details on dosage and duration not available
Number of subjects: 0
Study: 36453699

Group type: COMPARATOR
Intervention: Cervical pessary vs No treatment
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Cervical pessary vs Vaginal progesterone
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Cervical pessary vs Cervical cerclage
Number of subjects: 2983
Study: 36454054

Group type: EXPERIMENTAL
Intervention: Immunomodulatory and/or immunosuppressive (IM/IS) drugs
Number of subjects: 1672

Group type: COMPARATOR
Intervention: No treatment with IM/IS drugs (Control)
Number of subjects: 1672
Study: 36454186

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 0
Study: 36454322

Group type: EXPERIMENTAL
Intervention: Decalcified choroidal osteoma complicated by MNV
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Decalcified choroidal osteoma
Number of subjects: 28

Group type: COMPARATOR
Intervention: Calcified choroidal osteoma
Number of subjects: 28
Study: 36454567

Group type: EXPERIMENTAL
Intervention: Bridge HIV care continuum intervention
Number of subjects: 1225
Study: 36454631

Group type: EXPERIMENTAL
Intervention: Serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Underlying HIV infection
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Serologic evidence of prior CMV infection
Number of subjects: 280
Study: 36455049

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0
Study: 36455189

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 322
Study: 36455228

Group type: EXPERIMENTAL
Intervention: Trotabresib 30 mg/day on days 1-4 before surgery, followed by maintenance trotabresib 45 mg/day 4 days on/24 days off after surgery
Number of subjects: 20
Study: 36455412

Group type: EXPERIMENTAL
Intervention: Cobimetinib 60 mg once daily for 21 days followed by a 7-day break and concurrent intravenous atezolizumab 840 mg every 2 weeks (Cohort A)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cobimetinib for the first 14 days prior to initiation of atezolizumab on cycle 1 day 15 (Cohort B)
Number of subjects: 103
Study: 36455699

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO) worn for 3 months
Number of subjects: 7
Study: 36455999

Group type: EXPERIMENTAL
Intervention: Health professionals' perceptions and attitudes regarding children with early childhood caries and their families
Number of subjects: 0
Study: 36456014

Group type: EXPERIMENTAL
Intervention: Maternal age less than 18 years
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Being Muslim
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: First pregnancy
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Multiple births
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Male child
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Maternal education >5 years
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Maternal height ≥150 cm
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Being from wealthier families
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Vaginal bleeding
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Swelling
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (BP) in third trimester
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: High diastolic BP in third trimester
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Respiratory problem in third trimester
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Having poor appetite, nausea and vomiting in second trimester
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Having poor appetite, nausea and vomiting in third trimester
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Higher weight gain from second to third trimester
Number of subjects: 40119
Study: 36456026

Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis
Number of subjects: 645

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 645
Study: 36456066

Group type: EXPERIMENTAL
Intervention: Hemodynamically-guided management using an implanted pulmonary artery pressure sensor
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study: 36456068

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) LVAD implantation
Number of subjects: 2200
Study: 36456072

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val)
Number of subjects: 794
Study: 36456101

Group type: EXPERIMENTAL
Intervention: Whole blood RNA-sequencing (RNA-seq)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sixteen DE lncRNAs
Number of subjects: 23
Study: 36456193

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study: 36456200

Group type: EXPERIMENTAL
Intervention: N-acetyl-l-leucine (NALL) administered orally at 4 g/d for patients ≥13 years, weight-tiered doses for patients 6-12 years for 6 weeks.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: N-acetyl-l-leucine (NALL)
Number of subjects: 30
Study: 36456573

Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m) in combination with standard chemotherapy
Number of subjects: 233

Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy (NAC)
Number of subjects: 233
Study: 36456835

Group type: EXPERIMENTAL
Intervention: LNA043 (angiopoietin-like 3 derivative)
Number of subjects: 0
Study: 36457012

Group type: EXPERIMENTAL
Intervention: AO-COPD subjects
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 199
Study: 36457567

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Opioid-based anesthesia (OBA) group
Number of subjects: 48
Study: 36457575

Group type: EXPERIMENTAL
Intervention: Alpha particle-emitting isotopes (Radium-223, Actinium-225, Thorium-227)
Number of subjects: 0
Study: 36457825

Group type: EXPERIMENTAL
Intervention: Orthopedic surgery in aged mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery in mice
Number of subjects: 0
Study: 36457860

Group type: EXPERIMENTAL
Intervention: EPP-AF® (200 mg/day for 4 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (4 weeks without EPP-AF®)
Number of subjects: 37
Study: 36458416

Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 60
Study: 36458608

Group type: EXPERIMENTAL
Intervention: RAADS-R-DK
Number of subjects: 600
Study: 36458659

Group type: EXPERIMENTAL
Intervention: Deep learning approach using images from a magnetic endoscopic imaging (MEI) device for 5-class colorectal segment division
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Deep learning approach using images from a magnetic endoscopic imaging (MEI) device for 2-class colorectal segment division
Number of subjects: 1196
Study: 36458825

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg)
Number of subjects: 32
Study: 36459101

Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 17
Study: 36459100

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details on intervention not available.
Number of subjects: 0
Study: 36459227

Group type: EXPERIMENTAL
Intervention: NIV-NAVA
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 0
Study: 36459243

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 63
Study: 36459255

Group type: EXPERIMENTAL
Intervention: Glesatinib FBS 1050 mg twice daily
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Glesatinib SDD 750 mg twice daily
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Glesatinib (various formulations)
Number of subjects: 179
Study: 36459284

Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally twice daily in 28-day continuous cycles
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pamiparib
Number of subjects: 88
Study: 36459310

Group type: EXPERIMENTAL
Intervention: CRT-D replacement (REP)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Patients without persistent ICD indication at REP
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Predictive factors of sVAE
Number of subjects: 276
Study: 36459469

Group type: EXPERIMENTAL
Intervention: Resistance exercise (n = 71)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control (n = 60)
Number of subjects: 131
Study: 36459629

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36459673

Group type: EXPERIMENTAL
Intervention: Axatilimab (3 mg/kg given once every 4 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Axatilimab
Number of subjects: 40
Study: 36459691

Group type: EXPERIMENTAL
Intervention: STRO-002
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with carboplatin or Avastin
Number of subjects: 0
Study: 36459917

Group type: EXPERIMENTAL
Intervention: Actigraphy at medium threshold
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: aEEG
Number of subjects: 17

Group type: COMPARATOR
Intervention: Direct Observation (DO)
Number of subjects: 17
Study: 36459994

Group type: EXPERIMENTAL
Intervention: Inhalation of rhu-GM-CSF
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 81
Study: 36460027

Group type: EXPERIMENTAL
Intervention: Acoziborole (960 mg single dose)
Number of subjects: 208
Study: 36460211

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Strain echocardiography
Number of subjects: 132

Group type: COMPARATOR
Intervention: LGE-CMR
Number of subjects: 132
Study: 36460331

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Stool sample analysis for CoPEC detection and microbiota composition assessment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clinical data and survival outcomes collection
Number of subjects: 200
Study: 36460344

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36460537

Group type: EXPERIMENTAL
Intervention: Two-dose HPV vaccination program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-dose HPV vaccination program
Number of subjects: 0
Study: 36460655

Group type: EXPERIMENTAL
Intervention: aP booster vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 36460761

Group type: EXPERIMENTAL
Intervention: Femoral Neck System (FNS)
Number of subjects: 125
Study: 36460794

Group type: EXPERIMENTAL
Intervention: Opaganib 500 mg BID
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Opaganib (up to 750 mg BID)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Opaganib
Number of subjects: 13
Study: 36460852

Group type: EXPERIMENTAL
Intervention: Tourette syndrome
Number of subjects: 62
Study: 36460967

Group type: EXPERIMENTAL
Intervention: Out-of-hospital cardiac arrest (OHCA) cases treated by EMS
Number of subjects: 838

Group type: COMPARATOR
Intervention: Utstein comparator group
Number of subjects: 838
Study: 36461000

Group type: EXPERIMENTAL
Intervention: Enhanced Supportive Care (five sessions of symptom management and coping enhancement counseling by nurses)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Symptom monitoring (control group)
Number of subjects: 360